W-S Lee1, J N Lee, J-H Baek, Y H Park. 1. Department of Surgery, Gil Medical Center, Gachon University School of Medicine, 1198 Guwol-dong, Namdong-gu, Incheon, 405-760, Korea, lws@gilhospital.com.
Abstract
BACKGROUND: KRAS mutations are common and clearly contribute to malignant progression. The frequency of NRAS mutations and their relationship to clinical, pathologic, and molecular features remains unclear. METHODS: We evaluated 130 colorectal tumors for mutations in KRAS and NRAS gene. We tested for mutations in codons 61 and 146 of KRAS and codons 12, 13, 59, 61 and 146 of NRAS. Mutation status was determined by targeted dideoxy sequencing. RESULTS: Among the analyzed primary tumors, 36.2% had KRAS mutation. Of the 83 KRAS codon 12 and 13 wild-type patients, 7.2% had KRAS codon 61, 146 or NRAS. 40.7% harbored any RAS mutation. CONCLUSION: The frequency of other RAS (NRAS and KRAS exon 3, 4) activating mutations in colorectal cancers is relatively low in Korean colorectal cancer patients.
RCT Entities:
BACKGROUND:KRAS mutations are common and clearly contribute to malignant progression. The frequency of NRAS mutations and their relationship to clinical, pathologic, and molecular features remains unclear. METHODS: We evaluated 130 colorectal tumors for mutations in KRAS and NRAS gene. We tested for mutations in codons 61 and 146 of KRAS and codons 12, 13, 59, 61 and 146 of NRAS. Mutation status was determined by targeted dideoxy sequencing. RESULTS: Among the analyzed primary tumors, 36.2% had KRAS mutation. Of the 83 KRAS codon 12 and 13 wild-type patients, 7.2% had KRAS codon 61, 146 or NRAS. 40.7% harbored any RAS mutation. CONCLUSION: The frequency of other RAS (NRAS and KRAS exon 3, 4) activating mutations in colorectal cancers is relatively low in Korean colorectal cancerpatients.
Authors: C Bokemeyer; I Bondarenko; J T Hartmann; F de Braud; G Schuch; A Zubel; I Celik; M Schlichting; P Koralewski Journal: Ann Oncol Date: 2011-01-12 Impact factor: 32.976
Authors: Cecily P Vaughn; Scott D Zobell; Larissa V Furtado; Christine L Baker; Wade S Samowitz Journal: Genes Chromosomes Cancer Date: 2011-02-08 Impact factor: 5.006
Authors: F Loupakis; A Ruzzo; C Cremolini; B Vincenzi; L Salvatore; D Santini; G Masi; I Stasi; E Canestrari; E Rulli; I Floriani; K Bencardino; N Galluccio; V Catalano; G Tonini; M Magnani; G Fontanini; F Basolo; A Falcone; F Graziano Journal: Br J Cancer Date: 2009-07-14 Impact factor: 7.640
Authors: Carmen J Allegra; J Milburn Jessup; Mark R Somerfield; Stanley R Hamilton; Elizabeth H Hammond; Daniel F Hayes; Pamela K McAllister; Roscoe F Morton; Richard L Schilsky Journal: J Clin Oncol Date: 2009-02-02 Impact factor: 44.544
Authors: Michael Levi; Gintang Prayogi; Farid Sastranagara; Edi Sudianto; Grace Widjajahakim; Winiarti Gani; Albert Mahanadi; Jocelyn Agnes; Bela Haifa Khairunisa; Ahmad R Utomo Journal: J Gastrointest Cancer Date: 2018-06
Authors: Jin Ho Baek; Juhyung Kim; Dong Won Baek; Eunhye Chang; Hye Jin Kim; Su Yeon Park; Jun Seok Park; Gyu Seog Choi; Byung Woog Kang; Jong Gwang Kim Journal: Cancer Diagn Progn Date: 2022-01-03